Rockefeller Capital Management L.P. Global Blood Therapeutics, Inc. Transaction History

Rockefeller Capital Management L.P.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 12, 2022	BUY	$22.3 - $37.39 $1.24 Million - $2.08 Million	55,542 Added 23.84%	288,534 $9.22 Million
Q1 2022 May 13, 2022	BUY	$25.68 - $35.59 $233,328 - $323,370	9,086 Added 4.06%	232,992 $8.07 Million
Q4 2021 Feb 14, 2022	BUY	$24.9 - $40.26 $349,421 - $564,968	14,033 Added 6.69%	223,906 $6.55 Million
Q3 2021 Nov 12, 2021	BUY	$25.48 - $37.34 $1.18 Million - $1.73 Million	46,392 Added 28.38%	209,873 $5.35 Million
Q2 2021 Aug 10, 2021	BUY	$32.46 - $43.42 $4.54 Million - $6.08 Million	139,931 Added 594.19%	163,481 $5.73 Million
Q1 2021 May 11, 2021	BUY	$38.94 - $50.85 $440,022 - $574,605	11,300 Added 92.24%	23,550 $959,000
Q4 2020 Feb 12, 2021	SELL	$37.65 - $63.77 $199,394 - $337,725	-5,296 Reduced 30.18%	12,250 $530,000
Q3 2020 Nov 13, 2020	BUY	$52.76 - $74.49 $384,409 - $542,734	7,286 Added 71.01%	17,546 $967,000
Q2 2020 Aug 12, 2020	BUY	$48.73 - $81.82 $495,632 - $832,191	10,171 Added 11428.09%	10,260 $648,000
Q1 2020 May 12, 2020	BUY	$41.72 - $87.2 $3,587 - $7,499	86 Added 2866.67%	89 $5,000
Q4 2019 Feb 07, 2020	BUY	$45.7 - $81.86 $137 - $245	3 New	3 $0

288K

Ticker GBT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 67,476,200
Market Cap $4.62B
Description
Global Blood Therapeutics, Inc., a biopharmaceutical company, engages in the discovery, development, and delivery of treatments for underserved patient communities with sickle cell disease (SCD). The company offers Oxbryta tablets, an oral, once-daily therapy for SCD. It also evaluates the safety and pharmacokinetics of single and multiple doses...

Get notified when there are updates to the investment portfolio of Rockefeller Capital Management L.P., based on Form 13F filings with the SEC.

Stay updated on Rockefeller Capital Management L.P. with notifications on news.